Joel Elconin - Assessing Bond Market Intervention, Healthcare Strength, and Gold Stock Technicals
The KE Report Aug 20, 2026
Summary
The Treasury doubled long-dated bond buybacks to suppress 30-year yields near early-2000s highs, but the intervention does not address the underlying deficit.
Tech-driven corporate debt issuance and outsized equity returns are pulling capital away from Treasuries and eroding the classic 60/40 portfolio.
Moderna's 150% single-day move on cancer-therapy news showed how algorithmic trading can amplify swings in thin-float biotech names.
Healthcare's XLV ETF hit new 52-week highs as rotation into defensive sectors accelerated, partly aided by AI tailwinds.
GDXJ is testing resistance at 130-132 and needs sustained volume to confirm a breakout from its prior breakdown zone.
Joel Elconin's takeaways
- Top takeaway Joel's central view is that doubling long-end Treasury purchases "puts lipstick on a pig" — buybacks don't fix the deficit, debt issuance, or inflation risk, and the move looks like Treasury "fighting the Fed" and possibly telegraphing something.
- He argues the 60/40 portfolio is being broken by (a) tech issuers like Microsoft and Nvidia selling their own bonds to fund AI capex, and (b) equity returns — "25% in a day, 150% Modernas" — making a 5% Treasury yield feel like a real-terms loss.
- On hot algo-driven spikes like Moderna's $62.96-to-$174.38 print, Joel's rule is don't trade it that day — let the volatility settle, mark the regular-session high (he uses $176.66), note the after-hours print ($194.86), and wait for a clean technical setup.
- On beaten-down sectors like miners, his rule is to wait for prior support to act as resistance first; he's cautious on gold and silver until the old highs are retested and turned into support rather than chasing the August 7-10 breakout.
- On chart gaps, Joel's standing view is "most gaps are filled," citing Tesla's break through 40 as an example he is still waiting to get filled.